Neutralising antibodies in patients with multiple sclerosis treated with interferon beta-1b;Anticuerpos neutralizantes en pacientes con esclerosis multiple tratados con interferon beta-1b

Medicina Clinica

Volumn 114, Issue 5, 2000, Pages 169-170

  Río, Jordi ^a   Barberà, Narcis ^a   Tintoré, Mar ^a   Brieva, Luis ^a   Montalbán, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Interferon beta; Multiple sclerosis; Neutralising antibodies

Indexed keywords

INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ORTHOMYXOVIRUS;

EID: 0038629301     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71232-2     Document Type: Article

References (10)

1. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis group. Interferon beta-1b in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
2. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
3. Rice GPA, Paszner B, Oger J, Lesaux j, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology 1999; 52: 1277-1279.
4. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983; 13: 227-231.
5. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz T, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neuralizing antibodies. Neurology 1999; 52: 1239-1243.
6. Arnason B. Neutralizing antibodies: are they an issue? Int MSJ 1997; 4: 40-42.
7. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H et al. The effect of interferon beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-619.
8. PRIMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1 a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
9. Rio J, Nos C, Marzo ME, Tintoré M, Montalbán X. Low-oral steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998; 50: 1910-1912.
10. Paty OW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFN-1b: the use of an assay for neutralizing antibody. Neurology 1996; 47: 865-866.